SRNEQ · Sorrento Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $33.27M | $43.80M | - | $67.99M | $48.47M | $63.98M | - | $49.45M | $54.51M | $43.83M |
| SG&A | $48.94M | $54.98M | - | $50.16M | $48.14M | $44.33M | - | $48.49M | $50.39M | $43.39M |
| Total Operating Expenses | $92.26M | $122.59M | - | $126.84M | $129.82M | $125.27M | - | $113.45M | $114.06M | $99.16M |
| D&A | - | $3.62M | - | - | - | $3.30M | - | - | - | $2.92M |
| Operating Income | ($77.23M) | ($106.34M) | - | ($109.44M) | ($118.36M) | ($106.88M) | - | ($101.39M) | ($100.55M) | ($84.91M) |
| Interest Expense | $2.67M | $1.13M | - | $792.0K | $2.31M | $3.25M | - | $2.90M | $2.02M | $2.37M |
| Income Tax | $671.0K | $11.47M | - | ($1.01M) | ($1.05M) | $1.46M | - | $386.0K | ($641.0K) | ($206.0K) |
| Net Income | ($95.21M) | ($139.62M) | - | ($89.58M) | ($218.76M) | ($40.81M) | - | ($119.80M) | ($166.62M) | $2.51M |
| EPS - Basic | ($0.17) | ($0.26) | - | ($0.20) | ($0.54) | ($0.12) | - | ($0.40) | ($0.57) | $0.01 |
| EPS - Diluted | ($0.17) | ($0.26) | - | ($0.20) | ($0.54) | ($0.12) | - | ($0.40) | ($0.57) | $0.01 |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $69.75M | $37.66M | $23.63M | $70.69M | $70.34M | $111.91M | $36.66M | $39.73M | $77.29M | $41.68M |
| Accounts Receivable | $32.73M | $26.52M | $24.47M | $24.19M | $24.71M | $24.67M | $18.71M | $16.45M | $22.44M | $16.31M |
| Inventory | $9.65M | $11.31M | $9.98M | $17.96M | $20.70M | $14.09M | $8.11M | $5.43M | $2.68M | $1.78M |
| Accounts Payable | $18.55M | $14.59M | $47.52M | $38.39M | $24.94M | $25.02M | $27.41M | $27.84M | $33.97M | $25.06M |
| Current Assets | $133.11M | $100.76M | $96.37M | $176.96M | $196.05M | $331.12M | $172.99M | $200.72M | $155.26M | $265.70M |
| Total Assets | $456.69M | $460.06M | $472.84M | $615.61M | $632.13M | $855.64M | $694.82M | $752.79M | $778.92M | $613.62M |
| Current Liabilities | $264.95M | $165.63M | $327.92M | $201.98M | $145.32M | $204.23M | $139.45M | $175.18M | $180.45M | $96.04M |
| Long-term Debt | $21.74M | $21.40M | $19.13M | $17.80M | $83.07M | $96.08M | $110.63M | $83.50M | $82.57M | $79.96M |
| Total Liabilities | $654.65M | $587.48M | $494.51M | $485.41M | $496.37M | $629.44M | $616.69M | $621.46M | $593.39M | $382.73M |
| Stockholders' Equity | ($205.11M) | ($125.50M) | ($18.61M) | $131.85M | $132.02M | $226.54M | $78.75M | $131.50M | $186.17M | $231.44M |
| Retained Earnings | ($2.19B) | ($2.10B) | ($1.96B) | ($1.74B) | ($1.65B) | ($1.43B) | ($1.39B) | ($1.24B) | ($1.12B) | ($955.77M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($49.46M) | - | - | - | ($83.36M) | - | - | - | ($48.06M) |
| Investing Cash Flow | - | $1.68M | - | - | - | ($13.66M) | - | - | - | ($2.01M) |
| Financing Cash Flow | - | $61.20M | - | - | - | $173.37M | - | - | - | $35.36M |
| CapEx | - | $86.0K | - | - | - | $2.59M | - | - | - | $1.99M |
| Free Cash Flow | - | ($49.55M) | - | - | - | ($85.95M) | - | - | - | ($50.05M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 0.35 | - | - | - | 2.11 | - | - | - | -19.94 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | -8.9% |
| Return on assets | -20.8% | -30.3% | - | -14.6% | -34.6% | -4.8% | - | -15.9% | -21.4% | 0.4% |
| Return on equity | 46.4% | 111.2% | - | -67.9% | -165.7% | -18.0% | - | -91.1% | -89.5% | 1.1% |
| Return on invested capital | - | - | - | -57.8% | -43.5% | -26.2% | - | -37.3% | -29.6% | -27.3% |
| Liquidity | ||||||||||
| Current ratio | 0.50 | 0.61 | 0.29 | 0.88 | 1.35 | 1.62 | 1.24 | 1.15 | 0.86 | 2.77 |
| Quick ratio | 0.47 | 0.54 | 0.26 | 0.79 | 1.21 | 1.55 | 1.18 | 1.11 | 0.85 | 2.75 |
| Cash ratio | 0.26 | 0.23 | 0.07 | 0.35 | 0.48 | 0.55 | 0.26 | 0.23 | 0.43 | 0.43 |
| Leverage | ||||||||||
| Debt / Equity | -0.11 | -0.17 | -1.03 | 0.14 | 0.63 | 0.42 | 1.40 | 0.63 | 0.44 | 0.35 |
| Debt / Assets | 0.05 | 0.05 | 0.04 | 0.03 | 0.13 | 0.11 | 0.16 | 0.11 | 0.11 | 0.13 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -28.9x | -93.9x | - | -138.2x | -51.1x | -32.9x | - | -35.0x | -49.9x | -35.9x |
| Equity multiplier | -2.23 | -3.67 | -25.41 | 4.67 | 4.79 | 3.78 | 8.82 | 5.72 | 4.18 | 2.65 |
| Liabilities / Assets | 1.43 | 1.28 | 1.05 | 0.79 | 0.79 | 0.74 | 0.89 | 0.83 | 0.76 | 0.62 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 34.7% | 0.5% | - | -7.9% | -17.7% | -25.9% | - | -22.0% | -110.7% | -96.7% |
| Net income growth (YoY) | 56.5% | -242.1% | - | 25.2% | -31.3% | - | - | -42.6% | -114.3% | - |
| EPS growth (YoY) | 68.5% | -116.7% | - | 50.0% | 5.3% | - | - | -21.2% | -58.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 42.4% | - | - | - | -71.7% | - | - | - | -29.8% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | 0.3% | -29.1% | -2.1% | -52.3% | -36.0% | 35.6% | 129.0% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Sorrento Therapeutics against the 5 most active filers in the same SIC group.